Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock price shot up 3.9% during mid-day trading on Thursday . The company traded as high as $11.56 and last traded at $11.97. 796 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 6,236 shares. The stock had previously closed at $11.52.
Analyst Ratings Changes
Several research analysts recently commented on PHAR shares. HC Wainwright reissued a "buy" rating and set a $37.00 price target on shares of Pharming Group in a research report on Thursday, March 20th. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th.
Get Our Latest Stock Report on PHAR
Pharming Group Stock Down 6.0%
The company has a market capitalization of $739.57 million, a price-to-earnings ratio of -41.81 and a beta of 0.02. The firm's 50 day moving average price is $9.63 and its two-hundred day moving average price is $9.18. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The firm had revenue of $79.09 million for the quarter, compared to the consensus estimate of $67.74 million. Sell-side analysts anticipate that Pharming Group will post -0.2 earnings per share for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Featured Stories
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
